Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI
Laura Mauri
Raymond Gibbons
REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota
The largest study to date looking at long-term outcomes of bare metal stents as compared with drug eluting stents in patients who have undergone PCI was presented to the American Heart Association annual meeting. There was no increased mortality for patients who received drug eluting stents in a Massachussets based population. Sarah Maxwell spoke with investigator to Laura Mauri at the Orlando meeting.
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota
The largest study to date looking at long-term outcomes of bare metal stents as compared with drug eluting stents in patients who have undergone PCI was presented to the American Heart Association annual meeting. There was no increased mortality for patients who received drug eluting stents in a Massachussets based population. Sarah Maxwell spoke with investigator to Laura Mauri at the Orlando meeting.
